The major goal of this study was to compare mechanisms of the neuroprotective potential of 17 ␤-estradiol in two models for oxidative stress-independent apoptotic neuronal cell death with that in necrotic neuronal cell death in primary neuronal cultures derived from rat hippocampus, septum, or cortex. Neuronal apoptosis was induced either by staurosporine or ethylcholine aziridinium (AF64A), as models for necrotic cell death glutamate exposure or oxygen-glucose deprivation (OGD) were applied. Long-term (20 hr) pretreatment (0.1 M 17 ␤-estradiol) was neuroprotective in apoptotic neuronal cell death induced by AF64A (40 M) only in hippocampal and septal neuronal cultures and not in cortical cultures. The neuroprotective effect was blocked by the estrogen antagonists ICI 182,780 and tamoxifen and the phosphatidylinositol 3-kinase (PI3-K) inhibitor LY294002. In glutamate and OGD-induced neuronal damage, long-term pretreatment was not effective. In contrast, short-term (1 hr) pretreatment with 17 ␤-estradiol in the dose range of 0.5-1.0 M significantly reduced the release of lactate dehydrogenase and improved morphology of cortical cultures exposed to glutamate or OGD but was not effective in the AF64A model. Staurosporine-induced apoptosis was not prevented by either long-or short-term pretreatment. The strong expression of the estrogen receptor-␣ and the modulation of Bcl proteins by 17 ␤-estradiol in hippocampal and septal but not in cortical cultures indicates that the prevention of apoptotic, but not of necrotic, neuronal cell death by 17 ␤-estradiol possibly depends on the induction of Bcl proteins and the density of estrogen receptor-␣.
The neuroprotective potential of estrogens has gained increasing attention during the last years. Epidemiological evidence suggests that estrogen replacement therapy for postmenopausal women is associated with an improvement of some measures of cognitive performance, protection against cognitive deterioration, and decreased incidence of Alzheimer's disease (Paganini-Hill and Henderson, 1994; Robinson et al., 1994; Sherwin, 1994; Birge, 1996; Tang et al., 1996; Yaffe et al., 1998; Costa et al., 1999) . Moreover, beneficial effects of estrogen on the mortality and morbidity associated with cerebral stroke have been demonstrated (Lafferty and Fiske, 1994; Grodstein et al., 1996; Hurn and MacRae, 2000) . In a prospective 1 year study, however, estrogen failed to improve cognitive or functional outcomes of women with mild to moderate Alzheimer's disease (Mulnard et al., 2000) .
The efficacy of estrogen has been shown in several models of neurodegeneration and ischemic injury in vivo and in vitro. In ovariectomized rats, physiological concentrations of estradiol attenuated the extent of brain damage caused by permanent cerebral ischemia (Dubal et al., 1998) . Estradiol also alleviated stroke injury in reproductively senescent female rats . In primary neuronal cultures, organotypic hippocampal cultures and the hippocampal cell line HT22 estrogens attenuated neuronal injury caused by hypoxia, excitatory amino acids, superoxide anions, and hydrogen peroxide (Goodman et al., 1996; Singer et al., 1996; Behl et al., 1997; Regan and Guo, 1997; Weaver et al., 1997; Sawada et al., 1998) . Moreover, estradiol reduced the neurotoxic effects of ␤-amyloid as well as the generation of ␤-amyloid in cell cultures (Gridley et al., 1997; MookJung et al., 1997; Keller et al., 1997; Bonnefont et al., 1998; Xu et al., 1998; Pike, 1999) . The overexpression of ␤-amyloid precursor protein mRNA after focal ischemia in female ovariectomized rats was attenuated by a single subcutaneous injection of 17 ␤-estradiol (100 g/kg) 2 hr before middle cerebral artery occlusion (Shi et al., 1998) .
Until now, the efficacy of estradiol has been investigated mainly in models of neurodegeneration associated with excitotoxicity and oxidative stress. The aim of the present study was to evaluate the neuroprotective effect of estradiol in apoptotic neuronal cell death in vitro and to compare it with that in necrotic neuronal cell death. Apoptotic cell death in primary neuronal cell cultures derived from embryonic cortex, hippocampus, and septum was induced by ethylcholine aziridinium (AF64A) and staurosporine. AF64A, initially introduced as a model of cholinergic hypofunction (for review, see Hanin, 1996) has been shown to initiate neuronal cell death in vivo and in vitro by activating mechanisms of apoptosis (Rinner et al., 1997; Lautenschlager et al., 2000) . The mycotoxin staurosporine activates programmed cell death in virtually all cells (Falcieri et al., 1993; Raff et al., 1993; Bertrand et al., 1994) and induces neuronal apoptosis in primary neuronal cultures (Koh et al., 1995; Wiesner and Dawson, 1996) . Both AF64A and staurosporine have been demonstrated to initiate a caspase-dependent, free radical-independent apoptotic neuronal cell death in primary neuronal cultures . Either glutamate exposure or oxygen glucose deprivation (OGD) was used as a model for mainly necrotic types of neurodegeneration.
MATERIALS AND METHODS
Materials. 17 ␤-Estradiol (cyclodextrin-encapsulated), staurosporine, tamoxifen, cycloheximide, DMSO, and enzyme standard for the kinetic lactate dehydrogenase (LDH)-test were obtained from Sigma (Deisenhofen, Germany); LY 294002 was from C albiochem (Bad Soden, Germany); ICI 182,780 was from Tocris/ Biotrend Chemikalien (Köln, Germany); neurobasal medium and supplement B27 were from Life Technologies/ BRL (Eggenstein, Germany); modified Eagle's medium, PBS, H EPES buffer, trypsin / EDTA, penicillin -streptomycin, L-glutamine, collagen-G, and poly-L-lysine were from Biochrom (Berlin, Germany); multiwell plates were from Falcon (Franklin Lakes, NJ); Texas Red-labeled goat anti-mouse antibody were from Molecular Probes (Leiden, Holland); the mouse monoclonal antibody to estrogen receptor-␣ and the polyclonal (rabbit) antibody against estrogen receptor-␤ were from Alexis (Grünberg, Germany; no. 803-004-C050 and no. 210-135-C O50, respectively); ImmunoFluor mounting medium was from IC N (Eschwege, Germany); monoclonal antibodies to Bcl-2, Bcl-x L were from Transduction Laboratories (Lexington, K Y); monoclonal antibodies to Bax were from Santa Cruz Biotechnology (Heidelberg, Germany) and to ␣-fodrin were from Biotrend Chemikalien; proteinase inhibitor cocktail and antibodies to ␤-tubulin were from Boehringer Mannheim (Mannheim, Germany); secondary anti-mouse horseradish peroxidase-linked antibody was from Jackson Immunoresearch (West Grove, PA); enhanced chemiluminescence kits were from Amersham and Pierce (Rockford, IL); x-ray films were from Kodak (Germany); high-range molecular weight standard was from Sigma (St. L ouis, MO). AF64A was prepared from acetylethylcholine mustard (Research Biochemicals International, Natick, M A) according to Fisher et al. (1982) .
Primar y neuronal cell cultures. Primary neuronal cultures of hippocampus, septum, and cerebral cortex were obtained from embryos (E) (E16 -E18) of Wistar rats (Bundesinstitut f ür gesundheitlichen Verbraucherschutz und Veterinärmedizin, Berlin, Germany). Cultures were prepared according to Brewer (1995) with the following modifications. Septum, hippocampus, and cerebral cortex were dissected, incubated for 15 min in trypsin / EDTA (0.05/0.02% w/ v in PBS) at 36.5°C, rinsed twice with PBS and once with dissociation medium (modified Eagle's medium with 10% fetal calf serum, 10 mM H EPES, 44 mM glucose, 100 U penicillin ϩ streptomycin /ml, 2 mM L-glutamine, 100 I E insulin / l), dissociated by Pasteur pipette in dissociation medium, pelleted by centrif ugation (210 ϫ g for 2 min at 21°C), redissociated in starter medium (Neurobasal medium with supplement B27, 100 U penicillin ϩ streptomycin /ml, 0.5 mM L-glutamine, 25 M glutamate), and plated in 24-well plates or 6-well plates in a density of 200,000 cells per square centimeter. Wells were pretreated by incubation with poly-L-lysine (0.5% w/ v in PBS) for 1 hr at room temperature, then rinsed with PBS, followed by incubation with coating medium (dissociation medium with 0.03‰ w/ v collagen G) for 1 hr at 37°C, then rinsed twice with PBS before cells were seeded in starter medium. Cultures were kept at 36.5°C and 5% C O 2 and fed beginning from 4 d in vitro (DIV) with cultivating medium (starter medium without glutamate) by replacing half of the medium twice a week. The cell culture media and supplement B27 were free of estrogens.
Injur y paradigm. In all models the serum-free primary neuronal cultures were treated after 10 -14 DIV. The condition of cells at various time points after treatment was determined morphologically by phasecontrast microscopy.
AF64A (40 M) exposure was for 5 hr with subsequent rinsing and reapplication of conditioned medium. Controls received an equivalent amount of vehicle and were rinsed correspondingly.
Staurosporine was dissolved in DMSO (10 mM stock solution) and diluted with PBS to give the final concentrations of 100 and 300 nM in culture. The vehicle-treated cultures received the same amount of DMSO (in PBS) that was present in the highest dose of staurosporine.
For OGD, medium was removed from the cultures and preserved. Cultures were rinsed twice with PBS, then subjected to OGD for 120 min in a balanced salt solution at P O 2 Ͻ 2 mmHg, followed by replacement of the preserved medium as described previously (Bruer et al., 1997) . For standardization of the neuronal damage, the sister cultures were treated with an excess of glutamate (500 M; f ull kill).
Glutamate exposure was performed with 100 M glutamate for 30 min with subsequent rinsing and reapplication of conditioned medium.
Treatment with 17 ␤-estradiol, tamoxifen, ICI 182,780, LY 294002 , and c yclohe ximide. C yclodextrin-encapsulated 17 ␤-estradiol was dissolved in PBS and added to the cell cultures in a dose range of 30 nM to 10 M (final concentration in the medium) either 20 hr (long-term pretreatment) or 1 hr (short-term pretreatment) before the initiation of the injury. In the case of long-term treatment with glutamate toxicity, cells were washed twice with PBS, and the conditioned medium without 17 ␤-estradiol was replaced. Tamoxifen was dissolved in ethanol (10 mM stock solution) and diluted in water (100 M). The final concentrations in the medium were 1 M tamoxifen and 0.01% ethanol. ICI 182,780 and LY 294002 were dissolved in DMSO (100 and 65 mM stock solution, respectively). C ycloheximide dissolved in medium was added to give a final concentration of 500 ng /ml medium. Tamoxifen, ICI 182,780, LY 294002, or cycloheximide was added at the same time points as estradiol.
Cell death assays. Neuronal injury was quantitatively assessed by the measurement of LDH in the medium (Koh and Choi, 1987) at 72 hr after AF64A application, at 48 hr after staurosporine application, and at 24 hr after OGD and glutamate exposure.
Western blots. C ells were rinsed with PBS and harvested in lysis buffer containing (in mM): 150 NaC l, 1 C aC l 2 , 1 MgC l 2 , 10 Tris-HC l, pH 7.8, 1% Triton X-100, and proteinase-inhibitor mixture, incubated for 15 min on ice, and centrif uged (12,000 rpm, 4°C). Protein concentration was determined using the BCA protein assay (Pierce), and samples were diluted in SDS sample buffer and boiled for 3 min. Ten micrograms of protein per lane were loaded on 10.0% SDS-polyacrylamide minigels followed by electrophoresis. Blocking was performed semidry onto polyvinyldifluoride membranes, blocked with 5% nonfat dry milk, and detected with primary monoclonal antibodies to Bcl-2 (1:250), Bcl-x L (1:250), Bax (1:250), ␣-fodrin (1:1000), or ␤-tubulin (1:4000). A secondary anti-mouse horseradish peroxidase-linked antibody, enhanced chemiluminescence kits, and x-ray films were used to visualize signals. ␤-T ubulin served as a positive control for protein loading, and highrange molecular weight standard was used to determine protein sizes. C ell lysates served as positive controls for Bcl-2 and Bcl-x L according to the manufacturer. To provide semiquantitative analysis of band intensity, band densitometry was determined from scanned images of nonsaturated immunoblot films, using Scion Image, version Beta 4.0.2 software (Scion Corporation). To compare at least three different experiments, for each protein and brain region the pixel intensity of the bands obtained in each experiment was added and set as 100%. The individual band was calculated as percentage of total signals.
Immunoc ytochemistr y. For immunocytochemical analysis, cells were seeded onto glass coverslips and cultivated for 12 d. Cultures were then washed with PBS and fixed with freshly prepared 4% paraformaldehyde in PBS for 15 min at room temperature. C ells then were washed twice with PBS, permeabilized with 0.3% Triton X-100 in PBS, and exposed to blocking solution (PBS containing 10% goat serum and 1% BSA) for 30 min at room temperature. Cultures then were incubated with the mouse monoclonal antibody to estrogen receptor-␣ (5 g /ml) or with the polyclonal (rabbit) antibody against estrogen receptor-␤ (5 g /ml) for 48 hr at 4°C, washed three times in PBS, and developed with Texas Redlabeled goat anti-mouse antibody (dilution 1:500) for 30 min at room temperature. After being thoroughly rinsed with PBS, the cultures were placed on a glass slide in ImmunoFluor mounting medium (IC N, Eschwege, Germany) and observed by confocal microscopy. For negative controls, the primary antibody was omitted, resulting in no visible staining.
Confocal laser-scan microscopy and quantitative immunoc ytochemical evaluation. Quantitative immunocytochemical evaluation of cortical, septal, and hippocampal cultures was performed with an MRC600 confocal imaging system (Bio-Rad, Hemel Hempstead, UK) equipped with a Nikon Optiphot microscope as described previously (Gazzaley et al., 1996) . Briefly, an argon -krypton laser was used to excite Texas Red at 568 nm. The image was visualized using a Leitz 63/1.30 oil immersion objective. All of the confocal parameters were kept constant throughout the evaluation to yield unbiased comparisons of different neuronal cultures. The investigator was blinded throughout the evaluation and did not know from which brain area the culture was derived. Fifty fields from each culture were randomly selected and scanned at slow speed. Each digitized image consisted of 768 ϫ 512 pixels. The average pixel intensity of each cell in the field was selectively determined by a second blinded investigator using the CoMOS software program (Bio-Rad, Version 7.0a).
Terminal deoxynucleotidyl transferase-mediated biotinylated dUTP nick end labeling staining. Terminal deoxynucleotidyl transferase-mediated biotinylated dUTP nick end labeling (TUN EL) staining was performed with a commercially available ApopTag K it (Qbiogene, Heidelberg, Germany) according to the manufacturer's instructions. TUN ELpositive cells were analyzed for each injury paradigm in two independent preparations and were counted in a blinded manner in 20 randomly selected high-power fields. The investigator was not informed throughout the evaluation from which injury paradigm the culture was derived.
Data anal yses. Data are shown as means Ϯ SEM. To avoid possible variations of the cell cultures depending on the quality of dissection and seeding procedures, data were pooled from two to three representative experiments. For statistical analyses the one-way ANOVA was followed by T ukey's post hoc test.
RESULTS

␤-Estradiol protects hippocampal but not cortical neuronal cultures against AF64A-induced neurodegeneration in primary neuronal cultures
Long-term pretreatment with a single addition of 17 ␤-estradiol 20 hr before AF64A was associated with a marked reduction in LDH release in hippocampal and septal neurons 72 hr after toxin application ( Fig. 1) . The neuroprotective effect of 17 ␤-estradiol in hippocampal and septal neurons was achieved only at the lower dose range of 0.1 M and was not apparent at the higher dose of 1.0 M. No protection, however, was observed in cortical neurons. The AF64A-induced increase in LDH release from cortical neurons (90.4 Ϯ 9.3 U/ml) was not changed after pretreatment with 0.1 M (80.8 Ϯ 11.9) or 1.0 M 17 ␤-estradiol (96.9 Ϯ 8.8). In Figure 2a -c, representative phase-contrast micrographs of primary neuronal cultures from hippocampus under control condition and after AF64A exposure without and with long-term pretreatment with 17 ␤-estradiol are summarized. AF64A triggered morphological signs of apoptosis including degeneration of neurites, shrinkage of cell bodies, and fragmentation into condensed particles, which were at least partly prevented by pretreatment with 17 ␤-estradiol. In contrast, short-term pretreatment of cultured neurons with various doses of 17 ␤-estradiol 1 hr before AF64A application did not result in a significant reduction in LDH release within 72 hr after toxin exposure. The missing protection was obvious in cultures obtained from cortex, hippocampus, and septum (data not shown).
␤-Estradiol does not prevent staurosporine-induced neurodegeneration
In staurosporine-induced apoptotic neuronal cell death, neither short-term (1 hr) nor long-term (20 hr) pretreatment with 0.1 or 1.0 M 17 ␤-estradiol was effective in reducing the release of LDH. In the hippocampus the application of staurosporine (300 nM) induced an increase in LDH release from 77.2 Ϯ 5 to 128.6 Ϯ 8.2 U/ml 48 hr after addition (n ϭ 6 -12; p Ͻ 0.05). This increase was not significantly changed after short-term or long-term pretreatment with both doses of 17 ␤-estradiol (e.g., 138.7 Ϯ 3.0 and 136.2 Ϯ 11.8 after pretreatment with 0.1 M 17 ␤-estradiol, 1 and 20 hr before, respectively; n ϭ 6). Similarly in cortical cultures LDH release increased from 66 Ϯ 6.8 to 119.2 Ϯ 5.1 U/ml 48 hr after addition of staurosporine (300 nM; n ϭ 6 -12; p Ͻ 0.05) with no significant change of the increase after pretreatment with 17 ␤-estradiol (e.g., 121.9 Ϯ 7.3 and 130.6 Ϯ 9.6 U/ml after pretreatment with 0.1 M 17 ␤-estradiol, 1 and 20 hr before, respectively; n ϭ 6).
Only short-term pretreatment with 17 ␤-estradiol reduces LDH release from primary cortical cultures after glutamate exposure Exposure of cortical neurons to 100 M glutamate for 30 min induced marked neuronal cell death associated with a considerable increase in LDH release within 24 hr. Pretreatment of the cortical cultures with various doses of 17 ␤-estradiol 1 hr before glutamate attenuated the increase in LDH release. The neuroprotection was significant at 0.1 and 1.0 M but started to disappear at higher doses ( Fig. 3A ; Table 1 ). In phase-contrast microscopy, the protective effect of 17 ␤-estradiol was clearly visible (Fig. 2e,f ) . No neuroprotection was achieved after long-term pretreatment of the cultures with various doses of 17 ␤-estradiol (20 hr before 100 M glutamate), whereas in glutamate-treated sister cultures short-term pretreatment with 17 ␤-estradiol significantly reduced LDH release (Table 1) .
Only short-term pretreatment with 17 ␤-estradiol protects against neurodegeneration in cortical cultures induced by oxygen-glucose deprivation Comparable to its neuroprotective efficacy in glutamate-induced neuronal cell death, 17 ␤-estradiol was effective in OGD-related neuronal cell loss only after short-term pretreatment (1 hr). The effect was maximal in the dose range of 0.5-1.0 M (Fig. 3B) . In the presence of 0.5 M 17 ␤-estradiol, neurons appeared to be resistant against the influence of OGD (Fig. 2g-i) . At the dose of 0.1 M, which was effective as long-term pretreatment in the apoptotic model of neurodegeneration, 17 ␤-estradiol did not attenuate the release of LDH. No protection was achieved after long-term pretreatment with 17 ␤-estradiol (20 hr). In this experiment, the OGD-induced increase in LDH release from cortical neurons (59.7 Ϯ 7.0 U/ml) was not changed after pretreatment with 0.1 M (56.1 Ϯ 3.7), 0.5 M (64.5 Ϯ 7.5), or 1.0 M 17 ␤-estradiol (60.5 Ϯ 4.8).
Modulation of Bcl-2 expression by 17 ␤-estradiol in primary neuronal cultures
In hippocampal cultures, 17 ␤-estradiol (30 and 100 nM) increased the levels of Bcl-2 24 and 48 hr after application (Fig. 4 A) . Increased Bcl-2 levels persisted up to 68 hr after the addition of 17 ␤-estradiol (Fig. 5A) . At this late time point increased Bcl-x L levels were found. In contrast, we did not observe a change of the expression of Bcl-2 and Bcl-x L in cortical cultures after 17 ␤-estradiol treatment.
An increase in Bcl-2 expression also occurred 48 hr after the application of AF64A (40 M) in the hippocampal cultures. The pretreatment with 17 ␤-estradiol resulted in a further synergistic increase in Bcl-2 levels (Fig. 5A) . Levels of Bcl-x L and Bax were not altered 48 hr after AF64A treatment. Staurosporine rather suppressed the 17 ␤-estradiol-induced increase in Bcl-2 in the hippocampal neurons (Fig. 5B) . d, Vehicle-treated control cultures; e, cultures exposed to glutamate (100 M); f, cultures exposed to glutamate 1 hr after pretreatment with 17 ␤-estradiol (10.0 M); g, cultures exposed to OGD (2 hr); h, cultures exposed to OGD 1 hr after pretreatment with 17 ␤-estradiol (0.1 M); i, cultures exposed to OGD 1 hr after pretreatment with 17 ␤-estradiol (0.5 M).
Antagonism of long-term neuroprotective effect of estradiol by tamoxifen, ICI 182,780, and cycloheximide
To show that the long-term effect of estradiol is based on a receptor-mediated, transcription-regulating mechanism, we additionally treated hippocampal cultures with tamoxifen, ICI 182,780, or cycloheximide. The neuroprotective effect of 17 ␤-estradiol on AF64A-induced apoptotic cell death was abolished by receptor blockade as well as by inhibition of protein synthesis.
The results on LDH release are summarized in Table 2 . In addition, both tamoxifen and cycloheximide reduced the increase in the expression of Bcl-2 and Bcl-x L observed 48 hr after treatment with 17 ␤-estradiol (Fig. 4 B) . Tamoxifen, however, which has a comparable relative affinity for estrogen receptor-␣ versus estrogen receptor-␤ [7 and 6, respectively; see Kuiper et al. (1997) ], did not antagonize the neuroprotection by short-term treatment with 17 ␤-estradiol against glutamate exposure (Table 1) .
Lower expression of estrogen receptor-␣ in cortical neurons
To find out whether the neuroprotectivity of 17 ␤-estradiol against AF64A-induced apoptosis and the increase in Bcl expression depends on the presence of estrogen receptor-␣, we compared the expression of both estrogen receptor-␣ and estrogen receptor-␤ in the septal, hippocampal, and cortical neuronal cultures by immunocytochemical methods. The immunostaining for estrogen receptor-␣ was considerably weaker in the cortical neurons than in hippocampal and septal neurons (Fig. 6 A) . The intensity of immunoreactivity was quantified by means of confocal microscopy in 139 neurons of each culture system in a randomized, blinded manner. The mean pixel intensity was significantly higher in septal neurons (13.06 Ϯ 0.57) and hippocampal neurons (11.37 Ϯ 0.57) as compared with cortical neurons (7.62 Ϯ 0.47; p Ͻ 0.05, one-way ANOVA on ranks followed by Tukey's post hoc test). In addition, the immunoreactive neurons were differentiated according to fluorescence intensity. The median pixel intensity of all counted cells (8.9) was taken as a border between cells with low or high intensity. In cortical cultures, neurons with low fluorescence intensity prevailed (100 of 139 neurons). The opposite distribution was found in septal and hippocampal cultures (Fig. 6C) . In contrast, the immunostaining for estrogen receptor-␤ was more intense in the cortical neurons than in hippocampal and septal neurons (Fig. 6 B) . The intensity of immunoreactivity was quantified by means of confocal microscopy in 140 neurons of each culture system in a randomized, blinded manner. The mean pixel intensity was significantly lower in septal neurons (7.85 Ϯ 0.31) and hippocampal neurons (8.61 Ϯ 0.44) as compared with cortical neurons (10.86 Ϯ 0.39; p Ͻ 0.05, one-way ANOVA on ranks followed by Tukey's post hoc test). Again, the immunoreactive neurons were differentiated according to fluorescence intensity. The median pixel intensity of all counted cells (8.3) was taken as a border between cells with low or high intensity. In cortical cultures, neurons with high fluorescence intensity prevailed (91 of 140 neurons). The opposite distribution was found in septal and hippocampal cultures (Fig. 6C) .
Involvement of PI3-K cascade in the neuroprotectivity of 17 ␤-estradiol
As a further proof for the involvement of estrogen receptor-␣, we tested the influence of the inhibitor of PI3-K, LY294002, on the neuroprotectivity of 17 ␤-estradiol in the AF64A model. Activation of PI3-K is an important step in the insulin-like growth factor 1 (IGF-1) receptor pathway. It has been demonstrated recently that 17 ␤-estradiol induces an activation of this pathway only by stimulation of the estrogen receptor-␣ and not of the estrogen receptor-␤ (Kahlert et al., 2000) , When LY294002 was added (5 M) concomitantly with 17 ␤-estradiol, the protective effect of 17 ␤-estradiol was abolished completely ( Table 2) .
Assessment of apoptosis versus necrosis
To clearly differentiate between the mode of neuronal cell death in the various types of injury, we used two different approaches in addition to previously published distinctions. First, we compared the number of TUNEL-positive cells in cortical cultures per high power field (n ϭ 20) in the various conditions. The following numbers of TUNEL-positive cells were found: in control cultures, 6 Ϯ 2; 24 hr after glutamate exposure, 7.5 Ϯ 3; 24 hr after OGD, 3 Ϯ 2; 24 hr after staurosporine, 34 Ϯ 6; and 48 hr after addition of AF64A, 26 Ϯ 4. As a second approach the breakdown pattern of ␣-fodrin was analyzed to distinguish between necrosis and apoptosis. According to Nath et al. (1996) , ␣-fodrin is degraded to a 120 kDa fragment in apoptotic neurons but not in necrotic neurons (for review, see Wang, 2000) . A considerable increase in the 120 kDa fragment of ␣-fodrin was only found in staurosporine-treated cells and time dependently after AF64A treatment but not after exposure to glutamate or OGD (Fig. 7) .
The results of both techniques clearly indicate that in the case of AF64A and staurosporine the apoptotic cell death predominates, whereas in the case of glutamate and OGD cell death is necrotic in nature.
DISCUSSION
The present data provide in vitro evidence that different mechanisms are involved in the neuroprotective efficacy of estrogens depending on whether the injury model used is related to the apoptotic or necrotic type of neuronal cell death. Moreover, brain region-specific differences in neuroprotection by 17 ␤-estradiol were observed. In neuronal apoptotic cell death as induced by AF64A, neuroprotection was only achieved by long-term pretreatment with 17 ␤-estradiol in the 0.1 M dose range in hippocampal and septal but not cortical primary cultures. The neuroprotection was reversed both by the estrogen receptor antagonists ICI 182,780 and tamoxifen and by inhibition of protein synthesis. These findings indicate that prevention of apoptotic neuronal cell death is probably associated with transcriptional regulation, mediated by activation of estrogen receptors. Similar evidence has been obtained for the estrogen neuroprotection against ␤-amyloid in cultured hippocampal neurons (Pike, 1999) . Short-term mechanisms unrelated to estrogen receptors were not protective in the AF64A model for apoptotic neurodegeneration. When apoptotic cell death was induced by the broad spectrum protein kinase inhibitor staurosporine, hippocampal, septal, and cortical neurons were not protected after either long-term or short-term pretreatment with 17 ␤-estradiol. The failure of 17 ␤-estradiol to protect against staurosporine-induced apoptosis is explained at least partly by the following findings. First, it has been demonstrated in the present study that staurosporine prevents the 17 ␤-estradiol-induced expression of Bcl-2. Second, the inhibition of protein kinases by staurosporine could further contribute to the inefficacy of 17 ␤-estradiol. Estrogen neuroprotection in primary cortical neurons after glutamate excitotoxicity is mediated by activation of the mitogen-activated protein kinase signaling pathway (Singer et al., 1999) .
In neuronal injury caused by excitotoxicity or hypoxia, only short-term pretreatment and the use of higher doses of 17 ␤-estradiol (0.5-1.0 M) provided neuroprotection that was not prevented by estrogen receptor blockade. This is in agreement with previous results demonstrated in cortical, hippocampal, and mesencephalic dopaminergic cultures (Goodman et al., 1996; Behl et al., 1997; Regan and Guo, 1997; Sawada et al., 1998) . The independence of the neuroprotective effect of estrogen in excitotoxicity and hypoxia from estrogen receptor-mediated pathways or protein synthesis has been demonstrated by several groups (Sawada et al., 1998; Moosmann and Behl, 1999; Zaulyanov et al., 1999) . These findings and the immediate efficacy of higher doses of 17 ␤-estradiol indicate that mechanisms unrelated to transcrip- Effect of short-term (1 hr) and long-term (20 hr) pretreatment with 17 ␤-estradiol on the increase in LDH release (⌬ U/ml medium) tional regulation are involved, such as antioxidant properties of estrogens, direct inhibition of NMDA receptors (Weaver et al., 1997) , rapid release of calcium from intracellular stores (Beyer and Raab, 1998) , stimulation of guanylate cyclase activity (Chen et al., 1998) , blockade of calcium entry via L-type calcium channels (Mermelstein et al., 1996) , and stabilization of mitochondrial function . In addition, the involvement of a possible membrane-binding site on neurons for various steroids including estrogens is discussed (for review, see Behl and Holsboer, 1999) . Our finding of the inefficiency of 17 ␤-estradiol (0.1-5.0 M) after long-term pretreatment in glutamate and OGD-induced cell death is in contrast to the significant degree of protection against excitotoxicity observed in primary cortical neurons or hippocampal slice cultures, when low doses of 17 ␤-estradiol (1-50 nM) were added 24 hr before the excitotoxin (Singer et al., 1996; Bi et al., 2000) . In the hippocampal slice cultures, however, a comparable effect was observed whether the steroid was added 24 hr or 10 min before the excitotoxins (Bi et al., 2000) . The discrepancies between the latter and our studies might be related to the shorter period of exposure to the excitotoxin (Singer et al., 1996) or to the lower dose of excitotoxin in a completely different culture system (Bi et al., 2000) . The inefficacy of short-term pretreatment with 17 ␤-estradiol in the AF64A and staurosporine model for apoptosis agrees very well with the previous findings that in the same models various antioxidants, including melatonin, N-tert-butyl-␣-phenylnitrone, and dimethylthiourea, did not prevent neuronal cell death. In both models these antioxidants prevented the initial increase of malondialdehyde, indicating the accumulation of free radicals, but did not block the induction of apoptosis .
The brain region-specific differences in the neuroprotective efficacy of 17 ␤-estradiol in the case of apoptotic neuronal cell death are of considerable interest. We have observed that longterm pretreatment with 17 ␤-estradiol was effective only in hippocampal and septal cultures and did not attenuate the neuronal cell death induced by AF64A in cortical neuronal cultures. In contrast, cortical neurons pretreated with 17 ␤-estradiol for 1 hr became less vulnerable to excitotoxicity or OGD, an effect that was not antagonized by tamoxifen. Thus, receptor-independent effects of estradiol occur in cortical neurons, whereas modulations of gene activation do not exist or do not provide neuroprotection against AF64A in cortical cultures. One possible explanation is the differential distribution and regulation of estrogen receptor-␣ and estrogen receptor-␤ in the brain (Shughrue et al., 1997; Laflamme et al., 1998) . However, it is still a matter of debate which estrogen receptor subtype mediates the neuroprotective efficacy of estrogens. According to Sawada et al. (2000) , estradiol provides neuroprotection on nigral dopaminergic neurons by suppression of proapoptotic gene transcription through the AP-1 site via activation of estrogen receptor-␤. Moreover, in experimental stroke models, estrogen receptor-␣ deficiency does not enhance tissue damage in female animals, suggesting that estrogen inhibits brain injury by mechanisms that do not depend on activation of estrogen receptor-␣ (Sampei et al., 2000) . On the other hand, several lines of evidence support the involvement of estrogen receptor-␣. Evidence for a link between estrogen receptor-␣, Bcl-x L expression, and neuroprotection has been provided in cultured hippocampal neurons (Pike, 1999) . Moreover, in estrogen receptor-␣ knock-out mice, estradiol did not protect the brain against ischemic injury, indicating that estrogen receptor-␣ is a critical link in estradiol-mediated neuroprotection (Dubal et al., 2000) . Two findings of the present study also argue for a role of Figure 5 . A, Effect of 17 ␤-estradiol (0.1 M) and AF64A (40 M) on the expression of Bcl-2, Bcl-x L , Bax, and ␤-tubulin in hippocampal and cortical neuronal cultures. Neuronal cultures derived from hippocampus or cortex were maintained for at least 10 DIV before the experiment. Cells were treated with vehicle or 17␤-estradiol and 20 hr later with vehicle or AF64A. Cells were processed for Western blot 48 hr after application of AF64A. At least three separate experiments were performed. 1, Vehicle/vehicle-treated cultures; 2, 17␤-estradiol/vehicletreated cultures; 3, vehicle/AF64A-treated cultures; 4, 17␤-estradiol/ AF64A-treated cultures. The semiquantitative analysis of the Western blots of Bcl-2 and Bcl-x L by band densitometry from three separate experiments is shown. B, Effect of 17 ␤-estradiol (0.1 M) and staurosporine (300 nM) on the expression of Bcl-2 in hippocampal and cortical neuronal cultures. Neuronal cultures derived from hippocampus or cortex were maintained for at least 10 DIV before the experiment. Cells were treated with vehicle or 17␤-estradiol and 20 hr later with vehicle or staurosporine. Cells were processed for Western blot 24 hr after application of staurosporine. 1, Vehicle/vehicle-treated cultures; 2, 17␤-estradiol/ vehicle-treated cultures; 3, vehicle/staurosporine-treated cultures; 4, 17␤-estradiol/staurosporine-treated cultures. The semiquantitative analysis of the Western blots by band densitometry is shown from four separate experiments. Figure 6 . A, Immunocytochemical analysis on the localization of estrogen receptor-␣ ( A) and estrogen receptor-␤ ( B) in cortical, hippocampal, and septal neurons. Cells derived from cortex, hippocampus, or septum were cultivated for 12 d before they were fixed in 4% formaldehyde for 15 min at room temperature. After permeabilization with 0.3% Triton X-100 and exposure to blocking solution, cultures were incubated with the mouse monoclonal antibody to estrogen receptor-␣ or the polyclonal (rabbit) antibody against estrogen receptor-␤ for 48 hr at ϩ 4°C and developed with Texas Red-labeled goat antimouse antibody (1:500) for 30 min at room temperature. Cultures were placed on a glass slide in ImmunoFluor mounting medium and observed by confocal microscopy (magnification 630ϫ). C, Distribution of estrogen receptor-␣-and estrogen receptor-␤-immunoreactive neurons according to immunofluorescence intensity in cortical, hippocampal, and septal neuronal cultures. The quantitative immunocytochemical analysis was performed by means of confocal microscopy. The average pixel intensity was determined in 139 and 140 neurons, respectively, of each of the culture systems selected in a randomized, blinded manner. The median pixel intensity of all counted cells (8.9 and 8.3, respectively) was taken as a border between cells with low or high intensity. estrogen receptor-␣. First, the lowest immunofluorescence intensity for estrogen receptor-␣, but the highest immunofluorescence intensity for estrogen receptor-␤, appeared in the cortical cultures as compared with hippocampal and septal cultures. This is in agreement with in vivo findings in the adult rat (Shughrue et al., 1997; Laflamme et al., 1998) and confirms the recent finding by Zhang et al. (2000) that the expression of estrogen receptor-␣ was barely detectable in cultured neurons from embryonic rat cortex (E14). Second, the neuroprotectivity of 17 ␤-estradiol was abolished by the PI3-K inhibitor LY29402, which also has been reported previously (Honda et al., 2000) . This finding indicates a role of PI3-K in the estradiol-mediated neuroprotection and a possible involvement of the IGF-1 receptor pathway. This pathway is known to be activated by estrogen receptor-␣ but not by estrogen receptor-␤ (Kahlert et al., 2000) . It is well established that although both estrogen receptors exhibit the same affinity for 17 ␤-estradiol , the two forms of receptors display different patterns of affinities for naturally occurring hormone response elements, suggesting a different pattern of gene activation by the two receptors (Hyder et al., 1999) . This refers not only to the activation of IGF-1 receptor but also to the activation of the transcription at the AP-1 sites (Paech et al., 1997; Kahlert et al., 2000) .
The ability of 17 ␤-estradiol to modulate the expression of Bcl proteins was demonstrated first in peripheral, non-neuronal tissue (human breast cancer cells, in uterine endometrium during the proliferative phase of menstrual cycle) (Bhargava et al., 1994; Otsuki et al., 1994; Teixeira et al., 1995) . In the brain, an upregulation of Bcl-2 by estradiol was found in hypothalamic neurons of female rats in vivo (Garcia-Segura et al., 1998) . Estradiol prevents the downregulation of Bcl-2 expression in cerebral cortex of ovariectomized female rats induced by ischemic brain injury (Dubal et al., 1999) . Moreover, 17 ␤-estradiol significantly increases Bcl-x L levels in cultured hippocampal neurons (Pike, 1999) . In the present study we found an increase in Bcl-2 and Bcl-x L levels in cultured hippocampal and septal neurons up to 68 hr after treatment with 17 ␤-estradiol (30 -100 nM), whereas the same treatment did not change Bcl-2 and Bcl-x L levels in cortical neurons. After treatment with AF64A an increase in Bcl-2 expression was observed in hippocampal cultures, and the effect of 17 ␤-estradiol on Bcl-2 expression was intensified.
Although the dose range of 17 ␤-estradiol used in the present experiments is above the physiological and possible therapeutic range, our data may to some extent help to explain clinical findings. In Alzheimer's disease, where the cerebral cortex is affected as well, the first controlled prospective clinical trial of adequate duration to determine the benefit of estrogen did not support a role of estrogen for the treatment of this disease (Mulnard et al., 2000) . The lack of an effect of 17 ␤-estradiol in cortical neurons both on Bcl-2 and Bcl-x L expression and on protection against AF64A-induced apoptosis may provide an experimental basis for understanding the recently reported failure to slow disease progression in women with mild to moderate Alzheimer's disease. 
